The Ultibro Breezhaler is a prescription medication used in the management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is a combination inhaler that contains two active ingredients: indacaterol and glycopyrronium. Indacaterol is a long-acting beta2-adrenergic agonist (LABA) that helps to relax the muscles in the airways, making it easier to breathe, while glycopyrronium is a long-acting muscarinic antagonist (LAMA) that reduces the production of mucus and helps to keep the airways open. The Ultibro Breezhaler is designed for once-daily use, providing 24-hour relief from COPD symptoms. It is not intended for the relief of acute bronchospasm or for the treatment of asthma. Patients use the Breezhaler inhalation device to inhale the medication, which comes in the form of a dry powder.